Product Details
Product Details
Product Specification
| Species | Human |
| Accession | P01135 |
| Amino Acid Sequence | Val40-Ala89 |
| Expression System | E.coli |
| Molecular Weight | 30-33kDa (Reducing) |
| Purity | >95% by SDS-PAGE |
| Endotoxin | <1EU/μg |
| Conjugation | Unconjugated |
| Tag | No Tag |
| Physical Appearance | Lyophilized powder |
| Storage Buffer | 20mM Tris, 150mM NaCl, pH8.0 |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
Background
Transforming growth factor alpha (TGF-α), a polypeptide of 5.5kDa that is partially homologous to epidermal growth factor (EGF), is important in the control of glial and Schwann cell proliferation and survival of differentiated neurons. TGF-α is a mitogenic polypeptide that is able to bind to the EGF receptor/EGFR and to act synergistically with TGF-β to promote anchorage-independent cell proliferation in soft agar. Although TGF-α commonly acts via autocrine or paracrine signaling in solid tissues, it can also mediate paracrine signaling by activated macrophages, monocytes, neutrophils, and eosinophils.
Picture
Picture
Bioactivity

Measured in a cell proliferation assay using Balb/c 3T3 mouse fibroblast cells, The EC50 for this effect is less than 0.6ng/ml.
SDS-PAGE

1μg (R: reducing conditions, N: non-reducing conditions).
